[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569566":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":40,"locations":50,"responsibleParty":85,"collaborators":89,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":100,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":39,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":39,"overallStatus":53,"whyStopped":39,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"SCF Pharma","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1: Exploratory MAG-EPA treatment group","EXPERIMENTAL","This is a single arm phase of the study. Every subject will receive the experimental treatment (MAG-EPA) at 1,5g\u002Fday for a period of 8 weeks.",[13],"Dietary Supplement: Monoglyceride Eicosapentaenoic acid (omega-3)",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 2: MAG-EPA treatment group","This phase of the study is a parallel design. Subjects will be assigned to experimental treatment (MAG-EPA) by randomization. Every subject in this arm will receive the same treatment at 1,5g\u002Fday for a period of 16 weeks.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Phase 2: Placebo group","PLACEBO_COMPARATOR","This phase of the study is a parallel design. Subjects will be assigned to Placebo treatment (sunflower oil) by randomization. Every subject will receive the same treatment at 2,0g\u002Fday for a period of 16 weeks.",[23],"Other: Sunflower Oil",[25,32],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DIETARY_SUPPLEMENT","Monoglyceride Eicosapentaenoic acid (omega-3)","515 mg MAG-EPA + 33 mg MAG-DHA per capsule x 3 capsules daily: 1.5g\u002Fday (MAG-EPA). Subjects will be treated over a period of 56 days (or 112 days in phase 2) followed by a wash-out period of 28 days.",[9,15],[31],"MAG-EPA",{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"OTHER","Sunflower Oil","698 mg sunflower oil per capsule x 3 capsules: 2.0g\u002Fd sunflower oil (Placebo) Subjects will be treated over a period of 112 days followed by a wash-out period of 28 days.",[19],[38],"Placebo",null,[41,46],{"name":42,"role":43,"phone":44,"phoneExt":39,"email":45},"Samuel Fortin, Investigator, Ph.D","CONTACT","1-418-750-8590","sfortin@scfpharma.com",{"name":47,"role":43,"phone":48,"phoneExt":39,"email":49},"Anne-Julie Landry, Clinical Project Manager, M.Sc, DESS","4183607480","ajlandry@scfpharma.com",[51,72],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Institut de recherche clinique du littoral (IRCL)","RECRUITING","Maria","Quebec","G0C 1Y0","Canada","CA",{"type":60,"coordinates":61},"Point",[62,63],-65.98595,48.1749,{"lat":63,"lon":62},[66,69],{"name":47,"role":43,"phone":67,"phoneExt":39,"email":68},"418-360-7480","ajlandry@ircl.ca",{"name":70,"role":71,"phone":39,"phoneExt":39,"email":39},"Ludger Blier, MD, MD","SUB_INVESTIGATOR",{"facility":52,"status":53,"city":73,"state":55,"zip":74,"country":57,"countryCode":58,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Rimouski","G0K 1P0",{"type":60,"coordinates":76},[77,78],-68.52396,48.44879,{"lat":78,"lon":77},[81,84],{"name":82,"role":43,"phone":39,"phoneExt":39,"email":83},"Nancy Lemoignan, RN, ASN","nancylemoignan@hotmail.com",{"name":70,"role":71,"phone":39,"phoneExt":39,"email":39},{"type":86,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":39,"oldOrganization":39},"SPONSOR_INVESTIGATOR","Samuel Fortin","President",[90],{"name":52,"class":91},"UNKNOWN","100569566","phase-4-modulation-of-the-brain-fog-scale-by-eicosapentaenoic-acid-monoglycerides-mag-epa-100569566",false,"NCT06695910","Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).","Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA) in Volunteers Who Reported Suffering From Haze or Mental Fatigue on a Regular Basis. Exploratory Study (NBF-MG01).","NBF-MG01","Inclusion Criteria:\n\n1. Participant between 19 and 55 years of age.\n2. Participant who reports having mental fatigue and\u002For frequent memory loss and\u002For difficulty concentrating and\u002For inattention, confusion and\u002For a feeling of decreased cognitive acuity for at least 28 days at the time of selection.\n3. Participant who obtains a mean score on the BFS screening questionnaires (BFS1 and BFS2) total of at least 30 and\u002FOR who obtains the following minimum score on at least one of the three factors: Factor 1 of at least 15 and\u002For Factor 2 of at least 15 and\u002For Factor 3 of at least 12.\n4. Available for the entire duration of the study and willing to participate based on the information provided in the ICF duly read and signed by the latter.\n5. Absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements, ability to cooperate adequately, ability to understand and observe the instructions of the research staff.\n6. Participant having no difficulty in swallowing tablets, capsules or gelcaps.\n\nExclusion Criteria:\n\n1. Known allergy or intolerance to fish or history of allergic reactions attributable to fish, or to a compound similar to fish oil.\n2. Participant who has used omega-3 supplements in the 30 days preceding day 1 of the study.\n3. Pregnant or breastfeeding woman as declared by the latter.\n4. Presence of dependence on drugs of abuse or alcohol (˃ 3 units of alcohol per day, acute or chronic excessive consumption).\n5. Participant included in another clinical study and who is receiving an investigational product or other research treatment.",true,"ALL","19 Years","55 Years",{"count":105,"type":106},48,"ESTIMATED","INTERVENTIONAL",[109],"PHASE4","A growing body of studies shows that omega-3s act directly in molecular signaling pathways that reduce inflammation and are thought to have a positive effect on cognitive health. Brain fog is a term that has been popularized in the medical world in the wake of the COVID-19 pandemic. A significant proportion of patients with long COVID reported having cognitive sequelae that were like fogginess. It is defined as a cognitive impairment with characteristic symptoms including problems with concentration, attention and memory, confusion, difficulty understanding what others are saying, reduced mental acuity and mental fatigue. These are episodes of reduced cognitive capacity that are not representative of the person's normal state. This condition can be caused by various factors such as stress, lack of sleep, overwork, depression, hormonal changes due to pregnancy or menopause in women, head injuries, migraine, certain diseases or viral infections, certain medications as well as substance abuse (alcohol and\u002For street drugs). In this study, we want to test whether omega-3 monoglycerides (MAG-EPA) can modulate the cognitive health of people with brain fog.",[112,113],"Brain Fog","Cognitive Health","2025-12-04",{"date":116,"type":117},"2025-12-11","ACTUAL",{"date":119,"type":117},"2024-11-06",{"date":121,"type":106},"2027-07-01",{"name":87,"class":6},2]